2 results
Approved WMOCompleted
The primary objective is to demonstrate the efficacy of AR101, a pharmaceutical-grade peanut allergen formulation, through reduction in clinical reactivity to limited amounts of peanut allergen in peanut-allergic children (ages 4-17 years, inclusive…
Approved WMOCompleted
To evaluate the safety and tolerability of single ascending doses of UCB7853 administered as an iv infusion in healthy male study participantsTo evaluate the safety and tolerability of multiple (3 in total, given monthly) ascending doses of UCB7853…